6-Azuridine (Synonyms: 6-Azauridine)

目錄號: HY-131611 純度: 99.83%: FAQs
Data Sheet SDS COA 產品使用指南技術支持

6-Azuridine (6-Azauridine) 是一種嘌呤核苷類似物。嘌呤核苷類似物具有廣泛的抗腫瘤活性，靶向惰性淋巴系統(tǒng)惡性腫瘤。這一過程中的抗癌機制依賴于抑制 DNA 合成，誘導細胞凋亡 (apoptosis) 等。

MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務

6-Azuridine Chemical Structure

CAS No. : 54-25-1

1. 客戶無需承擔相應的運輸費用。

2. 同一機構（單位）同一產品試用裝僅限申領一次，同一機構（單位）一年內

可免費申領三個不同產品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
Free Sample (0.1 - 0.2 mg)		Apply now
10 mM * 1 mL in DMSO	￥680	In-stock
500 mg	￥620	In-stock
1 g	￥980	In-stock
5 g		詢價
10 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

6-Azuridine 相關產品

•相關化合物庫:

•同靶點產品:

•同靶點蛋白產品:

生物活性
純度 & 產品資料
參考文獻

生物活性

6-Azuridine (6-Azauridine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc^[1].

細胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
BHK-21	EC₅₀	> 100 μM Compound: NM299	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	> 100 μM Compound: NM 299	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
BHK-21	CC₅₀	> 100 μM Compound: NM 299	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	> 100 μM Compound: 6-Azauridine	Cytotoxicity against golden hamster BHK21 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against golden hamster BHK21 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29028528]
BHK-21	CC₅₀	> 100 μM Compound: NM 299	Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method	[PMID: 25913116]
BHK-21	EC₅₀	26 μM Compound: NM299	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	26 μM Compound: NM 299	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	26 μM Compound: 6-azauridine	Antiviral activity against YFV infected in BHK21 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against YFV infected in BHK21 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 18760610]
BHK-21	EC₅₀	46 μM Compound: NM 299	Antiviral activity against YFV infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method Antiviral activity against YFV infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method	[PMID: 25913116]
MT4	CC₅₀	0.2 μM Compound: NM 299	Cytotoxicity against human MT4 cells after 96 hrs by MTT method Cytotoxicity against human MT4 cells after 96 hrs by MTT method	[PMID: 18054491]
MT4	CC₅₀	2 μM Compound: NM299	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
MT4	CC₅₀	2 μM Compound: NM 299	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	CC₅₀	2 μM Compound: 6-Azauridine	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	2 μM Compound: NM 299	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	2 μM Compound: NM 299	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19482481]
MT4	CC₅₀	2 μM Compound: 6-azauridine	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 18760610]
Vero	CC₅₀	> 10 μM Compound: 6-Azauridine	Cytotoxicity against African green monkey Vero cells measured after 3 days by CelltiterGlo luminescence assay Cytotoxicity against African green monkey Vero cells measured after 3 days by CelltiterGlo luminescence assay	[PMID: 29277307]
Vero	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 100 μM Compound: NM 299	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: 6-Azauridine	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: 6-Azauridine	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: 6-Azauridine	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	CC₅₀	≥ 12.5 μM Compound: 6-AUdr	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining	[PMID: 22047799]
Vero	CC₅₀	≥ 12.5 μM Compound: 6-aza-uridine	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 22513121]
Vero	EC₅₀	0.9 μM Compound: NM 299	Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	1.2 μM Compound: 6-AUdr	Antiviral activity against Human respiratory syncytial virus A2 infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 5 days using crystal violet staining Antiviral activity against Human respiratory syncytial virus A2 infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 5 days using crystal violet staining	[PMID: 22047799]
Vero	EC₅₀	1.2 μM Compound: NM 299	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	1.2 μM Compound: NM 299	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	1.2 μM Compound: 6-Azauridine	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	1.4 μM Compound: 6-Azauridine	Antiviral activity against Rice stripe virus infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation by crystal violet staining Antiviral activity against Rice stripe virus infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	11 μM Compound: NM 299	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	11 μM Compound: NM 299	Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	CC₅₀	20 μM Compound: NM 299	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	[PMID: 19482481]
Vero	CC₅₀	20 μM Compound: 6-azauridine	Cytotoxicity against mock-infected african green monkey Vero76 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero76 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 18760610]
Vero	EC₅₀	4.48 μM Compound: 6-azauridine	Antiviral activity against PEDV infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by MTT assay Antiviral activity against PEDV infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by MTT assay	[PMID: 26698879]
Vero	CC₅₀	57.26 μM Compound: 6-azauridine	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 26698879]
Vero 76	EC₅₀	> 100 μM Compound: NM299	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	> 100 μM Compound: NM299	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	CC₅₀	> 12.5 μM Compound: 6-AU	Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 27161176]
Vero 76	EC₅₀	> 20 μM Compound: 6-azauridine	Antiviral activity against CVB2 infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against CVB2 infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	> 20 μM Compound: 6-azauridine	Antiviral activity against Sb1 virus infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against Sb1 virus infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	> 20 μM Compound: NM 299	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	CC₅₀	≥ 12.5 μM Compound: Aza	Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method	[PMID: 25014745]
Vero 76	EC₅₀	≥ 12.5 μM Compound: Aza	Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 26479028]
Vero 76	EC₅₀	1.2 μM Compound: 6-aza-uridine	Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 5 days by crystal violet staining Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 5 days by crystal violet staining	[PMID: 22513121]
Vero 76	EC₅₀	1.2 μM Compound: 6-azauridine	Antiviral activity against RSV infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against RSV infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	1.2 μM Compound: Aza	Antiviral activity against VSV Indiana ATCC VR-158 infected in african green monkey Vero-76 cells after 2 days by plaque reduction assay Antiviral activity against VSV Indiana ATCC VR-158 infected in african green monkey Vero-76 cells after 2 days by plaque reduction assay	[PMID: 26479028]
Vero 76	EC₅₀	1.2 μM Compound: 6-AU	Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay	[PMID: 27161176]
Vero 76	EC₅₀	1.2 μM Compound: NM299	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	1.2 μM Compound: Aza	Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in Vero 76 cells after 5 days by plaque reduction assays Antiviral activity against Human respiratory syncytial virus A2 ATCC VR-1540 infected in Vero 76 cells after 5 days by plaque reduction assays	[PMID: 25014745]
Vero 76	EC₅₀	1.2 μM Compound: NM 299	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	[PMID: 19482481]
Vero 76	CC₅₀	10 μM Compound: NM 299	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	12 μM Compound: 6-Azauridine	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining	[PMID: 26119992]
Vero 76	CC₅₀	16 μM Compound: 6-Azauridine	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]
Vero 76	CC₅₀	20 μM Compound: NM 299	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
Vero 76	CC₅₀	20 μM Compound: NM299	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]

分子量

245.19

Formula

C₈H₁₁N₃O₆

CAS 號

54-25-1

性狀

固體

顏色

White to off-white

中文名稱

氮雜尿苷

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性數據

細胞實驗：

DMSO 中的溶解度 : 25 mg/mL (101.96 mM; 超聲助溶; 吸濕的 DMSO 對產品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液

濃度溶劑體積質量	1 mg	5 mg	10 mg

1 mM	4.0785 mL	20.3923 mL	40.7847 mL
5 mM	0.8157 mL	4.0785 mL	8.1569 mL
10 mM	0.4078 mL	2.0392 mL	4.0785 mL

查看完整儲備液配制表

* 請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內使用，-20°C儲存時，請在1個月內使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據您的實驗動物和給藥方式選擇適當的溶解方案。

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結果的可靠性，澄清的儲備液可以根據儲存條件，適當保存；體內實驗的工作液，建議您現用現配，當天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現沉淀、析出現象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.20 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.20 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.20 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數量

只

由于實驗過程有損耗，建議您多配一只動物的量

請輸入您的動物體內配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網站選購。，Tween 80，均可在 MCE 網站選購。

計算結果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲備液濃度超過該產品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術支持聯系。

動物實驗體內工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產品資料

純度: 99.83%

選擇批次：

Data Sheet (622 KB) SDS (644 KB)

COA (292 KB) HNMR (252 KB) RP-HPLC (262 KB) LCMS (103 KB)

產品使用指南 (1538 KB)

參考文獻

[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. [Content Brief]

6-Azuridine 相關分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.0785 mL	20.3923 mL	40.7847 mL	101.9617 mL
	5 mM	0.8157 mL	4.0785 mL	8.1569 mL	20.3923 mL
	10 mM	0.4078 mL	2.0392 mL	4.0785 mL	10.1962 mL
	15 mM	0.2719 mL	1.3595 mL	2.7190 mL	6.7974 mL
	20 mM	0.2039 mL	1.0196 mL	2.0392 mL	5.0981 mL
	25 mM	0.1631 mL	0.8157 mL	1.6314 mL	4.0785 mL
	30 mM	0.1359 mL	0.6797 mL	1.3595 mL	3.3987 mL
	40 mM	0.1020 mL	0.5098 mL	1.0196 mL	2.5490 mL
	50 mM	0.0816 mL	0.4078 mL	0.8157 mL	2.0392 mL
	60 mM	0.0680 mL	0.3399 mL	0.6797 mL	1.6994 mL
	80 mM	0.0510 mL	0.2549 mL	0.5098 mL	1.2745 mL
	100 mM	0.0408 mL	0.2039 mL	0.4078 mL	1.0196 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

6-Azuridine54-25-16-Azauridine氮雜尿苷Nucleoside Antimetabolite/Analogindolent lymphoid malignanciesantitumorInhibitorinhibitorinhibit

產品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機構名稱：
留言給我們：

產品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機構名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質的科研機構、醫(yī)藥企業(yè)基于科學研究或藥證申報的用途提供醫(yī)藥研發(fā)服務，不為任何個人或者非科研性質的、非用于藥證申報使用等其他用途提供服務。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網安備31011502019417 滬(浦)應急管危經許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

6-Azuridine (Synonyms: 6-Azauridine)

Customer Review

6-Azuridine 相關產品

•相關化合物庫:

•同靶點產品:

•同靶點蛋白產品:

生物活性

純度 & 產品資料

參考文獻

摩爾計算器

稀釋計算器

6-Azuridine 相關分類

完整儲備液配制表

Keywords:

您最近查看的產品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

6-Azuridine (Synonyms: 6-Azauridine)

Customer Review

6-Azuridine 相關抗體

6-Azuridine 相關產品

•相關化合物庫:

•同靶點產品:

•同靶點蛋白產品:

生物活性

純度 & 產品資料

參考文獻

摩爾計算器

稀釋計算器

6-Azuridine 相關分類

完整儲備液配制表

Keywords:

您最近查看的產品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z